11:15 AM EDT, 09/04/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were flat late Wednesday morning, nudging 0.04% lower to 1,445.63 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies Genfit ( GNFT ) and Cellectis ( CLLS ) , which rose 3.8% and 2.6% respectively. They were followed by brewing company Anheuser-Busch InBev ( BUD ) and telecommunications company VEON (VEON), which were up 1.8% and 1.6% respectively.

The decliners from continental Europe were led by pharmaceutical company Ascendis Pharma ( ASND ) and biopharmaceutical company Calliditas Therapeutics ( CALT ) , which fell 12% and 2.6% respectively. They were followed by financial services company Banco Bilbao Vizcaya Argentaria ( BBVA ) , which lost 1.5%.

From the UK and Ireland, the gainers were led by biopharmaceutical company Biodexa Pharmaceuticals ( BDRX ) and software firm Endava ( DAVA ) , which increased 3.6% and 3.4% respectively. They were followed by biotech firm Autolus Therapeutics ( AUTL ) and telecommunications operator Vodafone Group ( VOD ) , which advanced 3.2% and 1.5% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company NuCana ( NCNA ) and biotech firm Trinity Biotech ( TRIB ) , which lost 8.1% and 4.4% respectively. They were followed by biopharmaceutical companies Adaptimmune Therapeutics ( ADAP ) and Amarin ( AMRN ) , which were down 2.5% and 1.8% respectively.